Literature DB >> 16251199

A segment of the Mecp2 promoter is sufficient to drive expression in neurons.

Megumi Adachi1, Edward W Keefer, Frederick S Jones.   

Abstract

Rett syndrome (RTT) is caused by mutations in the gene encoding methyl CpG-binding protein 2 (MeCP2). Although MeCP2 shows widespread expression in both neuronal and non-neuronal tissues, the symptoms of RTT are largely neurological. Herein, we have identified the regulatory region of the mouse Mecp2 gene that is sufficient for its restricted expression in neurons. A segment of the Mecp2 gene (-677/+56) exhibited strong promoter activity in neuronal cell lines and cortical neurons, but was inactive in non-neuronal cells and glia. The region necessary for neuronal-specific promoter activity was located within a 19 bp region (-63/-45). Several nuclear factors were found to bind to this region and some of these factors were enriched in nuclear extracts prepared from the brain. To examine the activity of the Mecp2 promoter in vivo, we generated transgenic mice expressing the LacZ reporter driven by the -677/+56 region of the Mecp2 gene. The transgene was expressed in the mesencephalon as early as embryonic day 10 and in the hindbrain and spinal cord by E12. Interestingly, a marked induction of transgene expression was observed postnatally throughout the brain, similar to that of endogenous MeCP2. However, expression of the transgene was absent in non-neuronal tissues that are known to express Mecp2. Taken together, these data indicate that the -677/+56 region of the Mecp2 promoter partially recapitulates the native expression pattern of the Mecp2 gene, which possesses restricted expression in neurons of the central nervous system.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16251199     DOI: 10.1093/hmg/ddi402

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  15 in total

Review 1.  Gene therapy for the nervous system: challenges and new strategies.

Authors:  Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

Review 2.  Rett syndrome and MeCP2.

Authors:  Vichithra R B Liyanage; Mojgan Rastegar
Journal:  Neuromolecular Med       Date:  2014-03-11       Impact factor: 3.843

3.  15q11.2-13.3 chromatin analysis reveals epigenetic regulation of CHRNA7 with deficiencies in Rett and autism brain.

Authors:  Dag H Yasui; Haley A Scoles; Shin-Ichi Horike; Makiko Meguro-Horike; Keith W Dunaway; Diane I Schroeder; Janine M Lasalle
Journal:  Hum Mol Genet       Date:  2011-08-12       Impact factor: 6.150

4.  Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors.

Authors:  Steven J Gray; Stacey B Foti; Joel W Schwartz; Lavanya Bachaboina; Bonnie Taylor-Blake; Jennifer Coleman; Michael D Ehlers; Mark J Zylka; Thomas J McCown; R Jude Samulski
Journal:  Hum Gene Ther       Date:  2011-06-01       Impact factor: 5.695

5.  Self-Complementary AAV9 Gene Delivery Partially Corrects Pathology Associated with Juvenile Neuronal Ceroid Lipofuscinosis (CLN3).

Authors:  Megan E Bosch; Amy Aldrich; Rachel Fallet; Jessica Odvody; Maria Burkovetskaya; Kaitlyn Schuberth; Julie A Fitzgerald; Kevin D Foust; Tammy Kielian
Journal:  J Neurosci       Date:  2016-09-14       Impact factor: 6.167

6.  Reduced MeCP2 expression is frequent in autism frontal cortex and correlates with aberrant MECP2 promoter methylation.

Authors:  Raman P Nagarajan; Amber R Hogart; Ynnez Gwye; Michelle R Martin; Janine M LaSalle
Journal:  Epigenetics       Date:  2006 Oct-Dec       Impact factor: 4.528

7.  MeCP2-mediated transcription repression in the basolateral amygdala may underlie heightened anxiety in a mouse model of Rett syndrome.

Authors:  Megumi Adachi; Anita E Autry; Herb E Covington; Lisa M Monteggia
Journal:  J Neurosci       Date:  2009-04-01       Impact factor: 6.167

8.  MECP2 isoform-specific vectors with regulated expression for Rett syndrome gene therapy.

Authors:  Mojgan Rastegar; Akitsu Hotta; Peter Pasceri; Maisam Makarem; Aaron Y L Cheung; Shauna Elliott; Katya J Park; Megumi Adachi; Frederick S Jones; Ian D Clarke; Peter Dirks; James Ellis
Journal:  PLoS One       Date:  2009-08-27       Impact factor: 3.240

9.  Novel MeCP2 isoform-specific antibody reveals the endogenous MeCP2E1 expression in murine brain, primary neurons and astrocytes.

Authors:  Robby M Zachariah; Carl O Olson; Chinelo Ezeonwuka; Mojgan Rastegar
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

10.  Brain region-specific expression of MeCP2 isoforms correlates with DNA methylation within Mecp2 regulatory elements.

Authors:  Carl O Olson; Robby M Zachariah; Chinelo D Ezeonwuka; Vichithra R B Liyanage; Mojgan Rastegar
Journal:  PLoS One       Date:  2014-03-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.